上海化源世纪贸易有限公司
上海市上海市普陀区
产品名：阿米替林
纯度：99.64%
规格：
联系人：徐经理
联系电话：13311869306

上海源溪生物科技有限公司
上海市上海市浦东新区
产品名：Amitriptyline；MK-230, N-750, Ro41575
纯度：98.9%
规格：1g
联系人：赖经理
联系电话：13564518121

上海创赛科技有限公司
上海市上海市嘉定区
产品名：[Perfemiker]3-(10，11-二氢-5H-二苯并[a，d]环庚烯-5-亚基)-N，N-二甲基丙基-1-胺,98%
纯度：98.0%
规格：5g/25g/100g
联系人：夏言
联系电话：18016376636

上海阿拉丁生化科技股份有限公司
上海市上海市浦东新区
产品名：阿米替林
纯度：98.0%
规格：1ml/1g/1g/1g
联系人：阿拉丁
联系电话：400-620-6333

查看所有供应商和价格请点击：

50-48-6生产厂家

50-48-6价格

50-48-6

50-48-6结构式

常用中文名：阿米替林
常用英文名：Amitriptyline
CAS号：50-48-6
分子式：C₂₀H₂₃N
分子量：277.40
相关类别：原料药神经系统用药抗抑郁、躁狂药
发布时间：2018-02-06 08:00:00
更新时间：2024-01-02 17:03:24
Amitriptyline 是一种常见的口服抗胆碱药。Amitriptyline 具有抗胆碱特性。Amitriptyline 可用于研究量化服用阿米替林与安慰剂患者的抗胆碱能不良反应。
阿米替林为临床最常用的三环类抗抑郁药，其药理作用是阻断去甲肾上腺素、5－羟色胺在神经末梢的再摄取，从而使突触间隙的递质浓度增高，促使突触传递功能而发挥抗抑郁作用。其抗抑郁作用相似于丙米嗪，可使抑郁症患者情绪提高，对思缓慢、行为迟缓及食欲不振等症状能有所改善。一般用药后7～10日可产生明显疗效。其镇静作用与抗胆碱作用比丙米嗪强。本品口服吸收完全，8-12小时血药浓度达高峰。在血中90％与血浆蛋白结合。部分经肝脏代谢为去甲替林，本产物仍有抗抑郁作用。由肾脏及肠道排出，排泄慢，24小时约排出40％，72小时排出60％。停药３周仍可在尿中检出。半衰期一般32－40小时。

化源商城直购

中文名	阿米替林
英文名	amitriptyline
中文别名	3-(10,11-二氢-5H-二苯并[a,d]环庚烯-5-亚基)-N,N-二甲基-1-丙胺
英文别名	Elavil EINECS 200-041-6 10,11-Dihydro-5-(g-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene Triptilin 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl- Triptanol Amitryptiline Tryptizol Euplit Lentizol 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine Amitriprolidine Sylvemid Proheptadiene 10,11-Dihydro-N,N-dimethyl-5H-dibenzo[a,d]cycloheptene-D5,g-propylamine Damilen Laroxyl Domical 3-(5,6-dihydrodibenzo[2,1-b:2',1'-f][7]annulen-11-ylidene)-N,N-dimethylpropan-1-amine 10,11-dihydro-5-(γ-dimethylaminopropylidene)-5H-dibenzo[a,d]cycloheptene 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-1-propanamine 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulén-5-ylidène)-N,N-diméthylpropan-1-amine 5-(3-Dimethylaminopropylidene)dibenzo[a,d][1,4]cycloheptadiene 3-(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethyl-1-propanamine Damitriptyline Saroten AMITID Amytriptiline 3-(10,11-Dihydro-5H-dibenzo[a,d][7]annulen-5-yliden)-N,N-dimethylpropan-1-amin Sarotex 5-(g-Dimethylaminopropylidene)-5H-dibenzo[a,d]-10,11-dihydrocycloheptene MFCD04971969 Miketorin Amineurin

描述	Amitriptyline 是一种常见的口服抗胆碱药。Amitriptyline 具有抗胆碱特性。Amitriptyline 可用于研究量化服用阿米替林与安慰剂患者的抗胆碱能不良反应。
相关类别	信号通路 >> 其他 >> 其他研究领域 >> 代谢疾病
参考文献	[1]. BrueckleMS, et al. Amitriptyline's anticholinergic adverse drug reactions-A systematicmultiple-indication review and meta-analysis. PLoS One. 2023 Apr5;18(4):e0284168.

密度	1.1±0.1 g/cm3
沸点	398.2±21.0 °C at 760 mmHg
熔点	196-197°C
分子式	C₂₀H₂₃N
分子量	277.40
闪点	174.0±18.9 °C
精确质量	277.183044
PSA	3.24000
LogP	4.92
蒸汽压	0.0±0.9 mmHg at 25°C
折射率	1.628
储存条件	2-8°C，干燥
水溶解性	9.7 mg/mL
分子结构	1、摩尔折射率：88.7 2、摩尔体积（cm³/mol）：262.7 3、等张比容（90.2K）：684.4 4、表面张力（dyne/cm）：47.3 5、极化率（10-24cm3）：35.16
计算化学	1.疏水参数计算参考值（XlogP）:无 2.氢键供体数量:0 3.氢键受体数量:1 4.可旋转化学键数量:3 5.互变异构体数量:无 6.拓扑分子极性表面积3.2 7.重原子数量:21 8.表面电荷:0 9.复杂度:331 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1
更多	1. 性状：不确定 2. 密度（g/mL,25/4℃）：不确定 3. 相对蒸汽密度（g/mL,空气=1）：不确定 4. 熔点（ºC）：196-197°C 5. 沸点（ºC,常压）：不确定 6. 沸点（ºC, 5.2 kPa）：不确定 7. 折射率：不确定 8. 闪点（ºC）：不确定 9. 比旋光度（º）：不确定 10. 自燃点或引燃温度（ºC）：不确定 11. 蒸气压（kPa,25 ºC）：不确定 12. 饱和蒸气压（kPa,60 ºC）：不确定 13. 燃烧热（KJ/mol）：不确定 14. 临界温度（ºC）：不确定 15. 临界压力（KPa）：不确定 16. 油水（辛醇/水）分配系数的对数值：不确定 17. 爆炸上限（%,V/V）：不确定 18. 爆炸下限（%,V/V）：不确定 19. 溶解性：水溶解性9.7 mg/mL

CHEMICAL IDENTIFICATION

RTECS NUMBER :: HO9275000

CHEMICAL NAME :: 5H-Dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10,11-dihydro-N,N-dimethyl-

CAS REGISTRY NUMBER :: 50-48-6

LAST UPDATED :: 199706

DATA ITEMS CITED :: 31

MOLECULAR FORMULA :: C20-H23-N

MOLECULAR WEIGHT :: 277.44

WISWESSER LINE NOTATION :: L C676 BY&T&J BU3N1&1

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 84 mg/kg

TOXIC EFFECTS :: Cardiac - EKG changes not diagnostic of specified effects

REFERENCE :: JJTOEX Japanese Journal of Toxicology. (Yakugyo Jihosha, Hokushin Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo, 101, Japan) V.1- 1988- Volume(issue)/page/year: 5,69,1992

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 60 mg/kg

TOXIC EFFECTS :: Cardiac - arrhythmias (including changes in conduction) Cardiac - change in rate Vascular - BP lowering not characterized in autonomic section

REFERENCE :: JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 19,67,1982

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - child

DOSE/DURATION :: 4500 ug/kg

TOXIC EFFECTS :: Behavioral - sleep

REFERENCE :: BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 3,663,1967

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 16800 ug/kg/2W-I

TOXIC EFFECTS :: Peripheral Nerve and Sensation - paresthesis Behavioral - headache

REFERENCE :: LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,426,1968

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human

DOSE/DURATION :: 14 mg/kg

TOXIC EFFECTS :: Cardiac - other changes

REFERENCE :: PSDTAP Proceedings of the European Society for the Study of Drug Toxicity. (Princeton, NJ 08540) V.1-15, 1963-74. For publisher information, see PESTD5. Volume(issue)/page/year: 6,171,1965

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - infant

DOSE/DURATION :: 50 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Cardiac - change in rate Behavioral - muscle contraction or spasticity

REFERENCE :: AJDCAI American Journal of Diseases of Children. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1-80(3), 1911-50; V.100- 1960- Volume(issue)/page/year: 130,507,1976

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 29 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: HETOEA Human & Experimental Toxicology. (Macmillan Press Ltd., Brunel Road, Houndmills, Basingstoke, Hampshire, RG21 2XS, UK) V.9- 1990- Volume(issue)/page/year: 9,257,1990

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 13500 ug/kg/3D-C

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Behavioral - excitement

REFERENCE :: LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,390,1968

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intramuscular

SPECIES OBSERVED :: Human - woman

DOSE/DURATION :: 240 ug/kg/36H-C

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold

REFERENCE :: LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 1,390,1968

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Human - man

DOSE/DURATION :: 45 mg/kg/21D

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Cardiac - change in rate

REFERENCE :: LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 2,1202,1972

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 320 mg/kg

TOXIC EFFECTS :: Behavioral - altered sleep time (including change in righting reflex) Behavioral - ataxia Gastrointestinal - changes in structure or function of salivary glands

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 15,863,1965

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 72 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: PJPPAA Polish Journal of Pharmacology and Pharmacy. (ARS Polona, POB 1001, 00-068 Warsaw 1, Poland) V.25- 1973- Volume(issue)/page/year: 27,503,1975

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 140 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: THERAP Therapie. (Doin, Editeurs, 8, Place de l'Odeon, F-75006 Paris, France) V.1- 1946- Volume(issue)/page/year: 26,459,1971

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 48400 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: FATOAO Farmakologiya i Toksikologiya (Moscow). For English translation, see PHTXA6 and RPTOAN. (V/O Mezhdunarodnaya Kniga, 113095 Moscow, USSR) V.2- 1939- Volume(issue)/page/year: 53(4),19,1990

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 100 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #4605673

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 16 mg/kg

TOXIC EFFECTS :: Behavioral - changes in motor activity (specific assay)

REFERENCE :: JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963- Volume(issue)/page/year: 17,65,1974

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Unreported

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 80 mg/kg

TOXIC EFFECTS :: Autonomic Nervous System - smooth muscle relaxant (mechanism undefined, spasmolytic)

REFERENCE :: JMCMAR Journal of Medicinal Chemistry. (American Chemical Soc., Distribution Office Dept. 223, POB POB 57136, West End Stn., Washington, DC 20037) V.6- 1963- Volume(issue)/page/year: 10,418,1967

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 50 mg/kg

TOXIC EFFECTS :: Peripheral Nerve and Sensation - spastic paralysis with or without sensory change Behavioral - muscle contraction or spasticity Lungs, Thorax, or Respiration - other changes

REFERENCE :: PHMCAA Pharmacologist. (American Soc. for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD 20014) V.1- 1959- Volume(issue)/page/year: 11,283,1969

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 58700 ug/kg

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - cyanosis

REFERENCE :: JTCTDW Journal of Toxicology, Clinical Toxicology. (Marcel Dekker, 270 Madison Ave., New York, NY 10016) V.19- 1982- Volume(issue)/page/year: 19,321,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rabbit

DOSE/DURATION :: 8600 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 15,863,1965

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 35 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: DRFUD4 Drugs of the Future. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1975/76- Volume(issue)/page/year: 8,949,1983 ** OTHER MULTIPLE DOSE TOXICITY DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 5760 mg/kg/22W-I

TOXIC EFFECTS :: Cardiac - EKG changes not diagnostic of specified effects Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death

REFERENCE :: ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 30,1709,1980

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 62500 ug/kg/30D-I

TOXIC EFFECTS :: Liver - other changes Kidney, Ureter, Bladder - other changes in urine composition Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - other Enzymes

REFERENCE :: TXCYAC Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973- Volume(issue)/page/year: 75,63,1992 ** REPRODUCTIVE DATA **

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 75 mg/kg

SEX/DURATION :: female 4-18 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - musculoskeletal system

REFERENCE :: JNMDBO Journal of Medicine (Westbury, NY). (PJD Pub., Ltd., POB 966, Westbury, NY 11590) V.1- 1970- Volume(issue)/page/year: 2,271,1971

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 504 mg/kg

SEX/DURATION :: female 6-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

REFERENCE :: PSDTAP Proceedings of the European Society for the Study of Drug Toxicity. (Princeton, NJ 08540) V.1-15, 1963-74. For publisher information, see PESTD5. Volume(issue)/page/year: 10,235,1969

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 252 mg/kg

SEX/DURATION :: female 6-14 day(s) after conception

TOXIC EFFECTS :: Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth)

REFERENCE :: PSDTAP Proceedings of the European Society for the Study of Drug Toxicity. (Princeton, NJ 08540) V.1-15, 1963-74. For publisher information, see PESTD5. Volume(issue)/page/year: 10,235,1969

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 540 mg/kg

SEX/DURATION :: female 8-16 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - other developmental abnormalities Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

REFERENCE :: PSDTAP Proceedings of the European Society for the Study of Drug Toxicity. (Princeton, NJ 08540) V.1-15, 1963-74. For publisher information, see PESTD5. Volume(issue)/page/year: 10,235,1969 *** REVIEWS *** TOXICOLOGY REVIEW DICPBB Drug Intelligence and Clinical Pharmacy. (POB 42435, Cincinnati, OH 45242) V.3- 1969- Volume(issue)/page/year: 8,690,1974 TOXICOLOGY REVIEW CLCHAU Clinical Chemistry (Winston-Salem, NC). (American Assoc. for Clinical Chemistry, 1725 K St., NW, Washington, DC 20006) V.1- 1955- Volume(issue)/page/year: 19,361,1973 TOXICOLOGY REVIEW CTOXAO Clinical Toxicology. (New York, NY) V.1-18, 1968-81. For publisher information, see JTCTDW. Volume(issue)/page/year: 2,403,1969 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X3816 No. of Facilities: 7 (estimated) No. of Industries: 1 No. of Occupations: 8 No. of Employees: 3157 (estimated) No. of Female Employees: 1154 (estimated)

危害码 (欧洲)	Xi
风险声明 (欧洲)	R36/37/38:Irritating to eyes, respiratory system and skin .
安全声明 (欧洲)	S26-S36
WGK德国	3
海关编码	2921499090

4317-14-0

~99%

50-48-6

文献：Gowda, Narendra B.; Rao, Gopal Krishna; Ramakrishna, Ramesha A. Tetrahedron Letters, 2010 , vol. 51, # 43 p. 5690 - 5693

1159-03-1

~75%

50-48-6

文献：Kupracz, Lukas; Kirschning, Andreas Advanced Synthesis and Catalysis, 2013 , vol. 355, # 17 p. 3375 - 3380

124-38-9

72-69-5

~83%

50-48-6

文献：Li, Yuehui; Sorribes, Ivan; Yan, Tao; Junge, Kathrin; Beller, Matthias Angewandte Chemie - International Edition, 2013 , vol. 52, # 46 p. 12156 - 12160 Angew. Chem., 2013 , vol. 125, # 46 p. 12378 - 12382,5

3433-80-5

50-48-6

文献：Kupracz, Lukas; Kirschning, Andreas Advanced Synthesis and Catalysis, 2013 , vol. 355, # 17 p. 3375 - 3380

1210-35-1

50-48-6

文献：Kupracz, Lukas; Kirschning, Andreas Advanced Synthesis and Catalysis, 2013 , vol. 355, # 17 p. 3375 - 3380

上游产品 6
4317-14-0 1159-03-1 124-38-9 72-69-5
3433-80-5 1210-35-1
下游产品 8
24755-73-5 72-69-5 1159-82-6 64520-05-4
549-18-8 16234-88-1 4317-14-0 4444-42-2

海关编码	2921499090
中文概述	2921499090 其他芳香单胺及衍生物及它们的盐. 增值税率:17.0% 退税率:9.0% 监管条件:无最惠国关税:6.5% 普通关税:30.0%
申报要素	品名, 成分含量, 用途
Summary	2921499090 other aromatic monoamines and their derivatives; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:30.0%

50-48-6	410074-74-7
549-18-8	1159-03-1
203645-63-0	342611-00-1
1159-82-6	111393-84-1
54063-24-0	37571-84-9
1158522-08-7	940364-43-2
134104-43-1	1396863-79-8
131615-57-1	6906-52-1
930439-75-1	1185247-85-1
1018584-77-4	1448037-10-2